Cargando…

Commentary: A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated with Initiation of Atypical Antipsychotic Therapy in Children and Adolescents

Detalles Bibliográficos
Autores principales:	Goltz, Jeffrey Samuel, Rice, Timothy Reynolds
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395636/ https://www.ncbi.nlm.nih.gov/pubmed/28469583 http://dx.doi.org/10.3389/fpsyt.2017.00059

Ejemplares similares

Effect of Betahistine and Metformin on Antipsychotic-Induced Weight Gain: An Analysis of Two Clinical Trials
por: Kang, Dongyu, et al.
Publicado: (2018)

The role of metformin in treatment of weight gain associated with atypical antipsychotic treatment in children and adolescents: A systematic review and meta-analysis of randomized controlled trials
por: Mansuri, Zeeshan, et al.
Publicado: (2022)

The Association Between Antipsychotics and Weight Gain and the Potential Role of Metformin Concomitant Use: A Retrospective Cohort Study
por: Hakami, Alqassem Y., et al.
Publicado: (2022)

Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial
por: de Boer, Nini, et al.
Publicado: (2021)

The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
por: Libowitz, Mark R., et al.
Publicado: (2021)

Antipsychotic-Induced Weight Gain and Clinical Improvement: A Psychiatric Paradox
por: Garcia-Rizo, Clemente
Publicado: (2020)

The potential effect of metformin on cognitive and other symptom dimensions in patients with schizophrenia and antipsychotic-induced weight gain: a systematic review, meta-analysis, and meta-regression
por: Battini, Vera, et al.
Publicado: (2023)

Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled Trial of Metformin for Antipsychotic-Induced Weight Gain in Patients with First-Episode Psychosis: A Pilot Study
por: Tang, Charmaine, et al.
Publicado: (2021)

Adjunctive metformin for antipsychotic-induced dyslipidemia: a meta-analysis of randomized, double-blind, placebo-controlled trials
por: Jiang, Wen-Long, et al.
Publicado: (2020)

Comparative Safety Signal Assessment of Hospitalization Associated With the Use of Atypical Antipsychotics
por: Yunusa, Ismaeel, et al.
Publicado: (2022)

S2. ANTIPSYCHOTICS RESULT IN WEIGHT GAIN BUT THE SEVERITY OF WEIGHT GAIN DIFFERS BETWEEN ANTIPSYCHOTICS
por: Bak, Maarten, et al.
Publicado: (2020)

Changes in energy during treatment of depression: an analysis of duloxetine in double-blind placebo-controlled trials
por: Harada, E, et al.
Publicado: (2015)

Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia
por: Yu, Zhi-min, et al.
Publicado: (2019)

Commentary: Neural Changes Associated with Treatment Outcome in Children with Externalizing Problems
por: Rice, Timothy R.
Publicado: (2016)

The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain
por: Li, Li, et al.
Publicado: (2021)

Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis
por: de Silva, Varuni Asanka, et al.
Publicado: (2016)

Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series
por: Prasad, Femin, et al.
Publicado: (2023)

Neuroleptic Malignant Syndrome After Re-introduction of Atypical Antipsychotics in a COVID-19 Patient
por: Espiridion, Eduardo D, et al.
Publicado: (2021)

Cardiovascular Risk of Concomitant Use of Atypical Antipsychotics and Stimulants Among Commercially Insured Youth in the United States
por: Zhang, Chengchen, et al.
Publicado: (2021)

Rating Opportunity for Long-Acting Injectable Antipsychotic Initiation Index (ROLIN)
por: Ifteni, Petru, et al.
Publicado: (2021)

Mechanisms of Perceived Treatment Assignment and Subsequent Expectancy Effects in a Double Blind Placebo Controlled RCT of Major Depression
por: Laferton, Johannes A. C., et al.
Publicado: (2018)

High-Dose Betahistine Improves Cognitive Function in Patients With Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial
por: Wang, Yongqian, et al.
Publicado: (2021)

Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review
por: Reynolds, Gavin P.
Publicado: (2012)

Commentary: Studying a Possible Placebo Effect of an Imaginary Low-Calorie Diet
por: Dickinson, Stephanie L., et al.
Publicado: (2020)

Synergistic Effects of Psychotropics Leading to Extraordinary Weight Gain
por: Kemp, Allyson J, et al.
Publicado: (2021)

Genetic and Metabolite Variability in One-Carbon Metabolism Applied to an Insulin Resistance Model in Patients With Schizophrenia Receiving Atypical Antipsychotics
por: Ward, Kristen M., et al.
Publicado: (2021)

A Commentary on “A New Initiative on Precision Medicine”
por: Ghitza, Udi E.
Publicado: (2015)

Association of MTHFR C677T Polymorphism With Antipsychotic-Induced Change of Weight and Metabolism Index
por: Su, Yi, et al.
Publicado: (2021)

Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome
por: Kornetova, Elena G., et al.
Publicado: (2019)

Acetazolamide for Antipsychotic-Associated Weight Gain in Schizophrenia
por: Kakunje, Anil, et al.
Publicado: (2018)

Efficacy and Safety of Adjunctive Aripiprazole, Metformin, and Paeoniae–Glycyrrhiza Decoction for Antipsychotic-Induced Hyperprolactinemia: A Network Meta-Analysis of Randomized Controlled Trials
por: Zhang, Ling, et al.
Publicado: (2021)

Influence of Identity Development on Weight Gain in Adolescent Anorexia Nervosa
por: Budde, Lynn I., et al.
Publicado: (2022)

Inverse Effects of Oxytocin on Attributing Mental Activity to Others in Depressed and Healthy Subjects: A Double-Blind Placebo Controlled fMRI Study
por: Pincus, David, et al.
Publicado: (2010)

Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers
por: Woelfl, Timo, et al.
Publicado: (2020)

Effect of atypical antipsychotics on body weight in geriatric psychiatric inpatients
por: Yeung, Eugene YH, et al.
Publicado: (2017)

Dietary fiber and probiotics for the treatment of atypical antipsychotic-induced metabolic side effects: study protocol for a randomized, double-blind, placebo-controlled trial
por: Liu, Chenchen, et al.
Publicado: (2021)

Efficacy and Safety of Cordyceps militaris as an Adjuvant to Duloxetine in the Treatment of Insomnia in Patients With Depression: A 6-Week Double- Blind, Randomized, Placebo-Controlled Trial
por: Zhou, Jiaojiao, et al.
Publicado: (2021)

Effect of Methylphenidate on Resting-State Connectivity in Adolescents With a Disruptive Behavior Disorder: A Double-Blind Randomized Placebo-Controlled fMRI Study
por: Pape, Louise, et al.
Publicado: (2021)

Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant
por: Khazaie, Habibolah, et al.
Publicado: (2022)

A Candidate Gliotransmitter, L-β-Aminoisobutyrate, Contributes to Weight Gain and Metabolic Complication Induced by Atypical Antipsychotics
por: Fukuyama, Kouji, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kf91b9u5vclau40rldbejd5fd0